Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AMRX 
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: AMRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.75
1 Year Target Price $11.75
| 1 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.04% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.78B USD | Price to earnings Ratio - | 1Y Target Price 11.75 |
Price to earnings Ratio - | 1Y Target Price 11.75 | ||
Volume (30-day avg) 4 | Beta 1.05 | 52 Weeks Range 6.50 - 9.47 | Updated Date 06/30/2025 |
52 Weeks Range 6.50 - 9.47 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.46% | Operating Margin (TTM) 14.51% |
Management Effectiveness
Return on Assets (TTM) 6.67% | Return on Equity (TTM) -881.26% |
Valuation
Trailing PE - | Forward PE 6.3 | Enterprise Value 5059012751 | Price to Sales(TTM) 1.34 |
Enterprise Value 5059012751 | Price to Sales(TTM) 1.34 | ||
Enterprise Value to Revenue 1.79 | Enterprise Value to EBITDA 9.22 | Shares Outstanding 313420000 | Shares Floating 167181148 |
Shares Outstanding 313420000 | Shares Floating 167181148 | ||
Percent Insiders 46.75 | Percent Institutions 44.24 |
Analyst Ratings
Rating 2 | Target Price 11.75 | Buy 3 | Strong Buy 1 |
Buy 3 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Amneal Pharmaceuticals, Inc. Class A Common Stock
Company Overview
History and Background
Amneal Pharmaceuticals, Inc. was founded in 2002. It has grown through acquisitions and organic growth, focusing on generic and specialty pharmaceuticals. The company has expanded its product portfolio and geographic reach over time.
Core Business Areas
- Generics: Develops, manufactures, and distributes generic pharmaceutical products across various therapeutic areas. These are low-cost alternatives to brand-name drugs once patents expire.
- Specialty: Focuses on developing and marketing branded specialty pharmaceutical products, often addressing specific medical needs or niche markets. This segment typically has higher profit margins but also involves more risk and investment.
- Injectables: Produces and markets injectable medications, a growing area due to the increasing demand for convenient and effective drug delivery systems.
Leadership and Structure
The leadership team consists of key executives overseeing different aspects of the business, such as R&D, manufacturing, sales, and finance. The organizational structure typically includes departments responsible for product development, regulatory affairs, commercial operations, and support functions.
Top Products and Market Share
Key Offerings
- Oral Solids: Amneal offers a wide range of generic oral solid medications. Market share varies significantly by product. Competitors include Teva Pharmaceutical Industries (TEVA), Mylan (VTRS), and Sandoz (part of Novartis, NVS). Revenue from these generics contributes significantly to the company's overall revenue.
- Injectables: Amneal's injectables portfolio continues to expand. The injectables market is competitive, with companies like Pfizer (PFE) and Hikma Pharmaceuticals among the major players. Revenue from injectables contributes a growing percentage of Amneal's revenues.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, increasing regulatory scrutiny, and pressure to reduce drug prices. Generics face pricing pressure while specialty drugs require significant investment in R&D and marketing.
Positioning
Amneal is a mid-sized player in the generics and specialty pharmaceuticals market. It aims to differentiate itself through a diversified product portfolio, efficient manufacturing, and strategic acquisitions.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated to be over $1 trillion. Amneal is positioned to capture a portion of this market through its generic and specialty products. The US generic market has been estimated at over $100 Billion.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Efficient manufacturing capabilities
- Established distribution network
- Experienced management team
Weaknesses
- High debt levels
- Dependence on generic drug approvals
- Exposure to pricing pressures
- Limited branded product pipeline
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions and partnerships
- Growth in emerging markets
- Increased demand for biosimilars
Threats
- Increased competition from other generic manufacturers
- Regulatory changes and pricing pressures
- Patent litigation and intellectual property risks
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- PRGO
Competitive Landscape
Amneal competes with larger generic pharmaceutical companies and faces pressure to maintain market share and profitability.
Major Acquisitions
Hayden-McNeil Pharmaceutical
- Year: 2018
- Acquisition Price (USD millions): 475
- Strategic Rationale: Expanded Amneal's reach in the prescription drug market and provided access to a broader range of products.
Growth Trajectory and Initiatives
Historical Growth: Amneal's historical growth has been driven by both organic expansion and strategic acquisitions.
Future Projections: Future growth is dependent on new product launches, market penetration, and the successful integration of acquired assets.
Recent Initiatives: Recent initiatives include investments in R&D, expansion of the product portfolio, and cost optimization programs.
Summary
Amneal Pharmaceuticals has a diversified product portfolio and efficient manufacturing capabilities, but faces challenges related to high debt, generic pricing pressures, and competition. Strategic acquisitions and expansion into new markets offer growth opportunities, but regulatory changes and patent litigation pose risks. The company needs to focus on reducing its debt, investing in branded products, and managing pricing pressures. The market share comparison needs updating based on real data.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Amneal Pharmaceuticals SEC Filings (10-K, 10-Q)
- Industry reports and market research
- Company press releases and investor presentations
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Exchange NYSE | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2009-01-15 | Co-Founder, Co-CEO, President & Director Mr. Chirag K. Patel | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8300 | Website https://www.amneal.com |
Full time employees 8300 | Website https://www.amneal.com | ||
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.